The insider selling is trivial in size and likely reflects post-earnings window opening and tax planning. The concurrent $500M ATM offering introduces potential dilution overhang, but the $500M buyback authorization partially offsets this. Monitor the pace of ATM usage and any insider purchases as a signal of management conviction.
Price Chart
Executive Summary
A cluster of insider selling at BridgeBio Pharma (BBIO) occurred in the week following the Q1 2026 earnings release and the filing of a $500M at-the-market (ATM) equity offering. CFO Thomas Trimarchi sold $678K in open-market shares, and Director Randal Scott sold $413K, while CEO Neil Kumar exercised options and surrendered shares for tax withholding. The total open-market sales of $1.09M represent ~0.009% of BBIO's $12.8B market cap, which is trivial. The cluster is likely driven by routine post-earnings blackout window opening and tax-related transactions, not a coordinated bearish signal.
Key Financial Metrics
Key Facts
- CFO Thomas Trimarchi sold 10,456 shares for $678K on May 18, 2026.
- Director Randal Scott sold 6,200 shares for $413K on May 15, 2026.
- CEO Neil Kumar exercised 33,544 options (non-cash) and surrendered 36,236 shares for tax withholding ($2.4M).
- Total open-market selling of $1.09M is only 0.009% of BBIO's $12.8B market cap.
- Q1 2026 revenue was $194.5M, including $180.6M in Attruby net product revenue.
- Company filed a $500M ATM equity offering on May 7, 2026, concurrent with a $500M share buyback authorization.
- Cash and marketable securities stood at $940.2M as of March 31, 2026.
Financial Impact
Open-market insider sales total $1.09M, which is immaterial relative to BBIO's $12.8B market cap.
Risk Factors
- The $500M ATM equity offering could dilute existing shareholders if fully utilized.
- Insider selling, while small, may continue if the stock appreciates further.
- Pipeline execution risk for BBP-418, encaleret, and infigratinib NDAs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1779222659731 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access